Genmab A/S
GMABNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $23.34B
- P/E (TTM)
- 29.61
- Forward P/E
- 36.72
- Dividend yield
- -
- 52-week range
- $23.62$40.17
- Volume (live)
- -
- Avg. volume (3M)
- 3.35M
Genmab A/S (GMAB) Stock Price & Financial Analysis
Genmab A/S Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $37.04 - $38.33 |
|---|---|
| 52-Week High | $40.17 |
| 52-Week Low | $23.62 |
| Open | $37.20 |
| Volume (last close) | 4.08M |
| Average Volume (3M) | 3.35M |
| Revenue (TTM) | 4.13B |
|---|---|
| Net Income (TTM) | 788.20M |
| Free Cash Flow (TTM) | 867.99M |
| EPS (TTM) | $1.58 |
| Profit Margin | 19.06% |
| Operating Margin | 32.29% |
| Return on Equity (ROE) | 13.23% |
| Debt to Equity | 0.89 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 23.34B |
|---|---|
| Shares Outstanding | 617.11M |
| P/E Ratio (TTM) | 29.61 |
| Forward P/E | 36.72 |
| Price to Sales (P/S) | 5.65 |
| Price to Book (P/B) | 3.92 |
| EV/EBITDA | 22.43 |
| 50-Day MA | $34.00 |
|---|---|
| 200-Day MA | $29.81 |
| 1-Year Change | +15.48% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Genmab A/S at a Glance
As of the Oct 15, 2026 close, Genmab A/S (GMAB) has a market capitalization of $23.34B. The stock trades at 29.6× trailing earnings, 36.7× forward earnings and 5.7× sales. Over the trailing twelve months it earned $788.20M on revenue of $4.13B (a 19.1% profit margin) and generated $867.99M of free cash flow. Revenue grew 18.1% year over year.
As of its latest reported balance sheet, it holds $1.50B in cash and securities against $5.27B of debt, a net debt position of $3.77B.
Genmab A/S does not currently pay a dividend.
The share price is up 15.5% over the past year. At $37.82 (the Oct 15, 2026 close) it sits near the top of its 52-week range of $23.62 to $40.17, above its 200-day moving average of $29.81.
Based on 11 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $112.22, 196.7% above the Oct 15, 2026 close.
Frequently Asked Questions About Genmab A/S
What is the current stock price for GMAB?
As of the Oct 15, 2026 close, GMAB stock trades at $37.82. The 52-week range is $23.62–$40.17, with a day range of $37.04–$38.33.
What is the P/E ratio for GMAB?
As of the Oct 15, 2026 close, Genmab A/S's trailing twelve-month (TTM) P/E ratio is 29.6, meaning investors pay $29.6 for every $1 of annual earnings. The forward P/E is 36.7, reflecting analyst expectations for future earnings. Genmab A/S operates in the Healthcare sector.
Does GMAB pay dividends?
Genmab A/S does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for GMAB?
Based on ratings from 11 professional analysts over the last 90 days, the consensus for GMAB is Buy. The average 12-month price target is $112.22, a 196.7% upside from the Oct 15, 2026 close of $37.82.
What is the market cap of GMAB?
As of the Oct 15, 2026 close, Genmab A/S's market capitalization is $23.34B, classifying it as a large-cap company. Genmab A/S operates in the Healthcare sector within the Biotechnology industry.